The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Susanne Nikolaus, Maria Angelica de Souza Silva, Hubertus Hautzel and Hans-Wilhelm Muller
Pages 130-147 (18)
Despite the knowledge, which has been accumulated on the central and peripheral actions of the neurokinin
(NK) substance P (SP) over the last 80 years, it is only beginning to receive the attention of nuclear medicine physicians
and scientists. Recently, two foci of interest have emerged: firstly, the performance of in vivo imaging studies of cerebral
NK1 receptor binding with non-peptidergic NK1 receptor radioligands, and, secondly, radionuclide therapy with radiolabelled
SP analogues targeting NK1 receptor binding sites. The present paper gives an overview on the utilization of nonpeptidergic
and peptidergic NK1 receptor radioligands in diagnostics and therapy.
Aprepitant, anxiety disorder, chronic pain, depression, epilepsy, glioma, NK1 receptor, substance P.
Clinic of Nuclear Medicine, University Hospital Dusseldorf, Moorenstr. 5, D-40225 Dusseldorf, Germany.